查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612875

Castleman氏病治療市場：按疾病類型、適應症、治療、應用分類 - 全球預測 2025-2030

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Castleman氏病治療市值為2.9433億美元，預計2024年將達到3.3415億美元，2030年將增加至7.1987億美元，預計複合年成長率為13.62%。

Castleman氏病(CD) 的治療重點是治療一種罕見疾病，涉及淋巴細胞過度生成，導致淋巴結腫大。治療方法包括免疫療法、皮質類固醇和單株抗體，旨在緩解症狀並改善患者的生活品質。 CD 治療的需要源於疾病的嚴重程度，可以是單中心或多中心的，並且需要量身定做的治療方法。治療主要在醫療保健機構中進行，並在醫院和專科診所進行。最終用途範圍包括醫療保健提供者、接受 CD 治療的患者以及開發標靶治療的製藥業。

主要市場統計
基準年[2023] 2.9433億美元
預測年份 [2024] 33415萬美元
預測年份 [2030] 71987萬美元
複合年成長率（%） 13.62%

市場成長的推動因素包括認知和診斷率的提高、生物療法的進步以及對罕見疾病研究的日益關注。新型免疫療法和個人化醫療方法的開發存在著充滿希望的機會。北美和歐洲是主要市場，主要是因為它們擁有先進的醫療基礎設施和積極的研究計劃。企業可以透過投資標標靶治療的研發以及與研究機構建立合作夥伴關係來抓住機遇，以促進創新。

然而，患者數量有限、治療成本高昂和監管障礙等挑戰可能會阻礙市場擴張。 CD 的綜合資料稀缺，這使得臨床試驗和核准過程變得複雜。此外，生物製藥價格昂貴，這可能會限制其可用性，特別是在開發中地區。

基因治療、生物標記發現和診斷技術改進等領域的技術創新進步可能為更有效的治療鋪平道路。您還可以透過與學術機構合作更好地了解疾病機制以及進行宣傳宣傳活動來提高早期診斷率來刺激業務成長。

CD 治療市場的特點是，由於不斷的研究和技術進步，它是一個動態波動的利基市場。制定解決市場限制的策略，同時專注於創新的治療解決方案，可確保持續成長和市場領導地位。

市場動態：快速發展的Castleman氏病治療市場的關鍵市場洞察

Castleman氏病治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • Castleman氏病流行和有效疾病管理的必要性
    • 用於治療Castleman氏病的孤兒藥指定和核准
    • 增加Castleman氏病治療的患者支持團體和意識計劃
  • 市場限制因素
    • Castleman氏病藥物開發的複雜性
  • 市場機會
    • 新Castleman氏病治療方法的開發不斷取得進展
    • Castleman氏病個人化醫療新趨勢
  • 市場挑戰
    • 缺乏標準化的治療通訊協定

波特五力：駕馭Castleman氏病治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解Castleman氏病治療市場的外部影響

外部宏觀環境因素在塑造Castleman氏病治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解Castleman氏病治療市場的競爭狀況

對Castleman氏病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣Castleman氏病治療市場供應商的績效評估

FPNV定位矩陣是評估Castleman氏病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了Castleman氏病治療市場的成功之路

對Castleman氏病治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • Castleman氏病的盛行率和有效疾病管理的必要性
      • 為Castleman氏病治療提供孤兒藥指定和核准
      • 患者支持團體的興起和卡斯爾曼治療的意識計劃
    • 抑制因素
      • Castleman氏病藥物開發的複雜性
    • 機會
      • 新Castleman氏病治療方法的開發不斷取得進展
      • Castleman氏病個人化醫療新趨勢
    • 任務
      • 缺乏標準化的治療通訊協定
  • 市場區隔分析
    • 疾病類型：由於潛在的全身器官衰竭，需要快速開發多中心Castleman氏病的治療策略
    • 適應症：越來越多採用Castleman氏病治療肝血管瘤淋巴瘤病例
    • 治療：化療的進步擴大了Castleman氏病治療方案的採用
    • 用途：透過提供最佳的患者照護來優先考慮門診手術中心
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Castleman氏病治療市場：依疾病類型

  • 多中心Castleman氏病
  • 單中心Castleman氏病

第7章Castleman氏病治療市場（按適應症）

  • 血管濾泡淋巴結增生
  • 肝血管瘤淋巴
  • 卡斯特曼瘤
  • 巨大良性淋巴瘤
  • 巨大淋巴結增生
  • 淋巴錯構瘤

第8章Castleman氏病治療市場（依治療）

  • 抗病毒藥物
  • 化療
  • 皮質類固醇
  • 免疫療法
  • 單株抗體
  • 放射治療

第9章Castleman氏病治療市場：依應用分類

  • 門診手術中心
  • 醫院

第10章 美洲Castleman氏病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太Castleman氏病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲Castleman氏病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准托珠單抗生物相似藥 Tofidence
    • Chugai 在日本獲得核准Actemra用於治療與癌症治療相關的細胞激素釋放症候群的額外適應症
    • Medable 與 Every Cure 合作，加速罕見疾病治療方法的發現
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Celltrion Healthcare Co.,Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals SA
  • Johnson & Johnson Services, Inc.
  • LGM Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer, Inc.
  • Recordati Group Company
  • Recordati SpA
  • Sanofi SA
  • Sartorius AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
Product Code: MRR-4312A385A340

The Castleman Disease Treatment Market was valued at USD 294.33 million in 2023, expected to reach USD 334.15 million in 2024, and is projected to grow at a CAGR of 13.62%, to USD 719.87 million by 2030.

Castleman Disease (CD) Treatment focuses on managing a rare disorder involving the overproduction of lymphatic cells, leading to enlarged lymph nodes. It encompasses therapies like immunotherapy, corticosteroids, and monoclonal antibodies aimed at mitigating symptoms and improving patients' quality of life. The necessity of CD treatment arises from the potential severity of the disease, which can manifest in unicentric or multicentric forms, necessitating tailored therapeutic approaches. Application is primarily in healthcare settings, with treatments administered in hospitals and specialty clinics. The end-use scope includes healthcare providers, patients undergoing CD therapy, and the pharmaceutical industry developing targeted treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 294.33 million
Estimated Year [2024] USD 334.15 million
Forecast Year [2030] USD 719.87 million
CAGR (%) 13.62%

Market growth is driven by increasing awareness and diagnosis rates, advances in biologic therapies, and a growing focus on rare disease research. Promising opportunities exist in the development of novel immunotherapies and personalized medicine approaches. North America and Europe are key markets, largely due to their advanced healthcare infrastructure and active research initiatives. Companies can seize opportunities by investing in R&D for targeted therapies and engaging in collaborations with research institutions to foster innovation.

However, challenges such as limited patient population, high treatment costs, and regulatory hurdles can hinder market expansion. There's a scarcity of comprehensive data on CD, complicating clinical trials and approval processes. Moreover, the high cost of biologic drugs may limit accessibility, especially in developing regions.

Innovation can thrive in areas like gene therapy, biomarker discovery, and enhanced diagnostic techniques, which could pave the way for more effective treatments. Business growth can also be spurred by exploring partnerships with academic institutions to understand disease mechanisms better and the creation of awareness campaigns to increase early diagnosis rates.

The CD treatment market is characterized by a niche focus with fluctuating dynamics due to ongoing research and technological progression. Building strategies that address market constraints while emphasizing innovative treatment solutions can ensure sustained growth and market leadership.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Castleman Disease Treatment Market

The Castleman Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Castleman disease and the need for effective disease management
    • Provision of orphan drug designation and approvals for Castleman disease treatments
    • Rise of patient advocacy groups and awareness programs for Castleman treatment
  • Market Restraints
    • Complexities in the drug development for Castleman disease
  • Market Opportunities
    • Ongoing advancements in the development of new Castleman disease treatment
    • Emerging trend of personalized medicine for Castleman disease treatment
  • Market Challenges
    • Lack fo standardized treatment protocols

Porter's Five Forces: A Strategic Tool for Navigating the Castleman Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Castleman Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Castleman Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Castleman Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Castleman Disease Treatment Market

A detailed market share analysis in the Castleman Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Castleman Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Castleman Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Castleman Disease Treatment Market

A strategic analysis of the Castleman Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Multicentric Castleman's Disease and Unicentric Castleman's Disease.
  • Based on Indication, market is studied across Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor, Giant Benign Lymphoma, Giant Lymph Node Hyperplasia, and Hamartoma of the Lyphatics.
  • Based on Treatment, market is studied across Antiviral Drugs, Chemotherapy, Corticosteroids, Immunotherapy, Monoclonal Antibodies, and Radiation Therapy.
  • Based on Application, market is studied across Ambulatory Surgical Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
      • 5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
      • 5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the drug development for Castleman disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
      • 5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack fo standardized treatment protocols
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure
    • 5.2.2. Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases
    • 5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
    • 5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Castleman Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Multicentric Castleman's Disease
  • 6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Angiofollicular Lymph Node Hyperplasia
  • 7.3. Angiomatous Lymphoid
  • 7.4. Castleman Tumor
  • 7.5. Giant Benign Lymphoma
  • 7.6. Giant Lymph Node Hyperplasia
  • 7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Antiviral Drugs
  • 8.3. Chemotherapy
  • 8.4. Corticosteroids
  • 8.5. Immunotherapy
  • 8.6. Monoclonal Antibodies
  • 8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Castleman Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Castleman Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Castleman Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
    • 13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
    • 13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Amgen Inc.
  • 4. Artiva Biotherapeutics, Inc.
  • 5. Bayer AG
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Biogen Inc.
  • 8. Boehringer Ingelheim GmbH
  • 9. Bristol-Myers Squibb Company
  • 10. Cadila Pharmaceuticals Limited
  • 11. Celltrion Healthcare Co.,Ltd.
  • 12. F. Hoffmann-La Roche AG
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Glenmark Pharmaceuticals S.A.
  • 16. Johnson & Johnson Services, Inc.
  • 17. LGM Pharma
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Octapharma AG
  • 21. Pfizer, Inc.
  • 22. Recordati Group Company
  • 23. Recordati S.p.A.
  • 24. Sanofi S.A.
  • 25. Sartorius AG
  • 26. Sun Pharmaceutical Industries Ltd.
  • 27. Takeda Pharmaceutical Company Limited
  • 28. Teva Pharmaceutical Industries Ltd.
  • 29. Thermo Fisher Scientific Inc.
  • 30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023